5.2% (16/310) had stage I disease, 31.3 % (97/310) had stageII, 46.5% (144/310) had stageIII, and 17.1% (53/310) had stageIV disease.
SPSS version 16.0 was used for statistical processing. Variance analysis was used for processing the enumerated data, a 字 2 test was used for measurement data, and a ranksum test was used for ranked data.
The time from the end of the first treatment to the first recurrence ranged from 4 months to 291 months, with a median recurrence time of 25 months, in which recurrence time less than 6 months accounted for 5.9% (20/337), 6 months to 12 months accounted for 17.8% (60/337), 12 months to 18 months accounted for 11.6% (39/337), and 18 months to 24 months accounted for 13.4% (45/337). The 2year cumulative recurrence cases accounted for 48.7% (164/337). Recurrence from 24 months to 60 months accounted for 34.4% (116/337), from 60 months to 120 months accounted for 13.6% (46/337), and recurrence time more than 120 months accounted for 3.3% (11/337), as seen in Figure 1 .
Nasopharyngeal recurrence alone was the most common [69.4% (234/337)]; followed by the concurrent recurrence in the nasopharynx and the cervical lymph nodes [26.1% (88/337) ]; Recurrence in the cervical lymph nodes alone was rare [4.5% (15/337)]. Total cumulative rate of distant metastasis before the end of treatment for recurrence was 6.8% (23/337), of which metastasis occurred 43.5% (10/23) in bone, 21.7% (5/23) in distant lymph nodes, 13.0% (3/23) in the lungs, 4.3% (1/23) in the liver, 13.0% (3/23) in multiorgan sites, and 4.3% (1/23) in the right parotid gland and the right medial canthus.
Patients with recurrent disease with no obvious symptoms accounted for 10.1% (34/337), whose recurrence was found only at periodic reexamination. The most common symptoms in symptomatic patients were epistaxis [38.0% (128/337)] and headache [31.5% (106/337)], followed by tinnitus, neck mass, nasal obstruction, and hearing loss, which were 16.9% (57/337), 14.8%
(95/337), 14.8% (95/337), and 11.9% (40/337), respectively. Other unusual symptoms included blurred vision, a sense that ears were plugged, facial edema, and epiphora; such symptoms did not exceed 3% . In addition, abducens dysfunction and facial nerve palsy caused by cranial nerve damage were common symptoms in patients with recurrent NPC, accounting for 35.3% (119/337), of which the most common was for the damage of the abduction nerve and trigeminal nerve branch 2, accounting for 19.9% (67/337) and 19.3% (65/337), respectively, followed by the damage of trigeminal nerve branches 1 and 3, accounting for 10.1% (34/337) and 9.5% (32/337), respectively. The rate of other cranial nerve injuries was below 5%. The positive rate of EBVVCA IgA in whole group was 98.6%, and the geometric mean titer of VCAIgA was 1:169.8. The positive rate of EAIgA was 65.6%, and the geometric mean titer was 1:31.8. The geometric mean titers of VCAIgA and EAIgA were 1:224.7 and 1:35.5, respectively, when patients were newly diagnosed in this group. The four sets of titer values were transformed logarithmically, and examined by Wilcoxon signed rank test. It was found that the Z value of logVCAIgA between the first diagnosis and recurrence was 2.768, which was statistically significant ( = 0.006); the value of logEAIgA between the first diagnosis and recurrence was 1.487, which was not statistically significant ( = 0.137).
The common invasion sites of recurrent NPC revealed by imaging in the whole group included the base of the skull base, accounting for 54.6% (184/337), the prestyloid space for 44.2% (149/337), the carotid sheath area for 32.3% (109/337), the anterior group of cranial nerves for 28.2% (95/337), the cavernous sinus for 26.1% (88/337), the paranasal sinuses for 22.8% (77/337), the oropharynx for 19.3% (65/337), the nasal cavity for 18.1% (61/337), intracranial invasion for 12.8% (43/337), the pterygomaxillary fossa for 11.0% (37/337), the posterior group of cranial nerves for 5.9% (20/337), the infratemporal fossa for 5.3% (18/337), the orbital apex for 5.0% (17/337), the soft palate for 3.3% (11/337), the cervical vertebrae for 2.1% (7/337), and the hypopharynx for 0.6% (2/337). Sites of primary and recurrent tumor invasion were compared by McNemar test (Table 1 ). The results showed that the invasion Figure 1 The time log of 337 patients with recurrent nasopharyngeal carcinoma rates of the oropharynx, the prestyloid space, and the carotid artery sheath by the primary tumor were significantly higher than those by the recurrence. Conversely, the invasion rates of the skull base, the paranasal sinuses, the cranial nerves, the cavernous sinus, the intracranial space, the pterygomaxillary fossa, the infratemporal fossa, the orbital apex, and the soft palate by recurrent tumors were significantly higher than those by the primary tumor. 89 the median age of patients with recurrent NPC is 43.8 years to 48 years, with a median recurrence time of 2 years, which is similar to this study. As reported by Lee . 9 and Cui . 10 the male:female ratio was about 2.5:1 and was similar with primary NPC. 15 In this study the male:female ratio was 3.6:1 and was very close to the 3.7:1 reported by Li et al.8 The results showed that the incidence of recurrent NPC was higher in men than in women, and the male:female ratio was even higher than it was 10 years ago. The ratio of recurrent cases declined gradually following the extended interval from the end of treatment. Patients with recurrent disease at 3 years after the initial diagnosis accounted for 63.5% , which were considered at high risk for recurrence. Patients with recurrent disease between 3 years and 6 years was 23.7% , which decreased by nearly twothirds compared to patients with recurrence at 3 years.
Patients with recurrence at 6 years to 10 years accounted for only 9.5% , which indicated a lowrisk period. Only very few patients were seen with disease recurrence after 10 years (3.3% ), who belonged to the stable period of cured NPC.
Two types of recurrence, including local nasopharyngeal recurrence and regional cervical lymph node recurrence, are present in patients with recurrent NPC. The incidence of these two types of recurrence has changed significantly over time. In the late 1970s, lymph node recurrence alone accounted for 43.4% of all patients with recurrent NPC, reported by Cao . 11 In the late 1980s, lymph node recurrence was 25.7%, reported by Cui . 10 In this group, nasopharyngeal recurrence alone was the most common, while lymph node recurrence alone accounted for only 4.5%. The reason is very likely that 渊1冤 the advancement of radiotherapeutic equipment and technology improved the local control rate of cervical lymph node metastases, and 渊2冤 combined chemotherapy and radiotherapy improved local control rates, especially for huge lymph nodes receiving radiotherapy after induction chemotherapy.
It was reported 23 in patients with primary NPC, cervical lymph node enlargement was the first symptom in about 40% to 50% of patients, followed by epistaxis, nasal obstruction, and tinnitus, etc. However, in this group, because nasopharyngeal recurrence alone accounted for the vast majority, neck mass only accounting for 14.8% of chief complaints, patients with recurrent disease reported headaches significantly more often than newly diagnosed patients, which might be due to late stage, destruction at the base of the skull, and/or intracranial invasion. In addition, the incidence of cranial nerve injury is 10.4% to 19.8% in primary NPC, 23, 12 but our data showed that in patients with recurrent disease, the incidence of cranial nerve injury occurred in onethird (35.3% ) of the patients, which is significantly higher than its incidence in newly diagnosed patients. This may be relevant to the wide variation in patients with recurrent NPC.
The results showed the pathologic type of recurrent NPC was still mainly WHO type III, which was similar to the pathologic type of newly diagnosed patients in regions with high incidence. The base of the skull is the most common site of recurrence, but it is hard to perform biopsy due to the deep position and the complicated surrounding anatomical structure. So in this group, patients with skull base or intracranial recurrence alone could only be diagnosed by combined clinical manifestations and imaging data.
In terms of the serological tests of EBV, Cao . 13 reported that VCAIgA and EAIgA levels correlated with clinical stages in newly diagnosed patientsthe higher the stage, the higher the antibody levelwhile the antibody levels of different clinical stages had no significant difference in this group. However, we found that the VCAIgA geometric mean titer of recurrent NPC was lower than that of primary disease, and the difference was statistically significant ( =0.006). Therefore, a lower level of VCAIgA does not equate with a decreased risk of recurrence.
By comparing the invasion sites between primary and recurrent tumors, specifically structures adjacent to the nasopharynx, such as the oropharynx, the prestyloid space, and the carotid artery sheath, the probability of invasion can be observed to be significantly lower in recurrent NPC. Conversely, regarding the structures far from the nasopharynx, such as the skull base, the paranasal sinuses, the cranial nerves, the cavernous sinus, the intracranial cavity, the pterygomaxillary fossa, the infratemporal fossa, the orbital apex, and the soft palate, the probability of invasion is significantly higher in recurrent disease than in primary disease. Areas neighboring the nasopharynx were in the highdose area during the first treatment, while the areas far away from the nasopharynx were in either low or nodose areas. So we speculate that the possible reasons for the abovementioned phenomena are: (1) the tumor cells of subclinical lesions in lowdose areas receive mostly sublethal damage, and can be repaired, survive, continue to split, and lead to tumor recurrence; or (2) the patients carry genes susceptible to NPC, and had a tendency of recurrence under external factors, but the normal structure of the areas adjacent to the nasopharynx was destroyed by highintensity rays at the first treatment, with the local blood supply reduced and unfavorable for tumor growth, so the tumor relocates and occurs far away from the nasopharynx.
The followup of patients with cancer is very important. Followup should be performed every 3 months in the first 3 years after treatment, and every 6 months thereafter, and imaging examinations should be performed every year to discover metastasis or recurrence before clinical symptoms appear. However, our data showed that the early diagnosis of patients with recurrent NPC was still unsatisfactory. Based on the 1992 Fuzhou staging criteria or 2002 UICC/AJCC staging system, earlystage patients (stages I/II) accounted for only about onequarter, while the vast majority of patients were at middle and latestages of disease. These patients have broader lesions and may have developed radiation encephalopathy or other consequences after their first treatment, so the area and dose of reirradiation is restricted, making it difficult to apply radical
